These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1597212)

  • 61. Lack of activity of omeprazole against Helicobacter pylori.
    Cariani G; Vandelli A; Santini D; Aversa GP; Fontana G
    Am J Gastroenterol; 1991 Nov; 86(11):1690. PubMed ID: 1951259
    [No Abstract]   [Full Text] [Related]  

  • 62. [Antibacterial activity of cefdinir and omeprazole against Helicobacter pylori and their inhibition on H. pylori-producing urease].
    Yokoya Y; Ikeda F; Mine Y
    Kansenshogaku Zasshi; 1993 Sep; 67(9):808-15. PubMed ID: 8409593
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Omeprazole may kill Helicobacter pylori.
    Goh KL; Tan KK; Anderson PE
    Am J Gastroenterol; 1991 Jan; 86(1):124. PubMed ID: 1986547
    [No Abstract]   [Full Text] [Related]  

  • 64. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism.
    McGowan CC; Cover TL; Blaser MJ
    Gastroenterology; 1994 Sep; 107(3):738-43. PubMed ID: 8076759
    [No Abstract]   [Full Text] [Related]  

  • 65. Antimicrobial susceptibility testing before first-line treatment for
    Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
    World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Negative Effect of Proton-pump Inhibitors (PPIs) on Helicobacter pylori Growth, Morphology, and Urease Test and Recovery after PPI Removal--An In vitro Study.
    Saniee P; Shahreza S; Siavoshi F
    Helicobacter; 2016 Apr; 21(2):143-52. PubMed ID: 26222264
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Suppression of Helicobacter pylori colonization with omeprazole.
    Fukuda Y
    Scand J Gastroenterol Suppl; 1996; 214():54-5; discussion 57-60. PubMed ID: 8722408
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Endogenous dopamine and duodenal bicarbonate secretion in humans.
    Knutson L; Knutson TW; Flemström G
    Gastroenterology; 1993 May; 104(5):1409-13. PubMed ID: 8482451
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats.
    Lal MA; Körner A; Matsuo Y; Zelenin S; Cheng SX; Jaremko G; DiBona GF; Eklöf AC; Aperia A
    Diabetes; 2000 Aug; 49(8):1381-9. PubMed ID: 10923641
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antioxidant activity of nitecapone and its analog OR-1246: effect of structural modification on antioxidant action.
    Marcocci L; Suzuki YJ; Tsuchiya M; Packer L
    Methods Enzymol; 1994; 234():526-41. PubMed ID: 7808329
    [No Abstract]   [Full Text] [Related]  

  • 71. Determination of nitecapone and (13C6)nitecapone in human plasma by gas chromatography/mass spectrometry.
    Ottoila P; Pakkala E; Karlsson C; Taskinen J
    Biol Mass Spectrom; 1991 Dec; 20(12):771-6. PubMed ID: 1812986
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine.
    Taskinen J; Wikberg T; Ottoila P; Kanner L; Lotta T; Pippuri A; Bäckström R
    Drug Metab Dispos; 1991; 19(1):178-83. PubMed ID: 1673395
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enhanced clearing of Helicobacter pylori after omeprazole plus roxithromycin treatment.
    Cellini L; Marzio L; Di Girolamo A; Allocati N; Grossi L; Dainelli B
    FEMS Microbiol Lett; 1991 Dec; 68(3):255-7. PubMed ID: 1804757
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.
    Sjöström JE; Larsson H
    J Med Microbiol; 1996 Jun; 44(6):425-33. PubMed ID: 8636959
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In-vitro activity of lansoprazole against Helicobacter pylori.
    Figura N; Crabtree JE; Dattilo M
    J Antimicrob Chemother; 1997 May; 39(5):585-90. PubMed ID: 9184356
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
    Nagahara A; Sato N
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():421-5. PubMed ID: 16363572
    [No Abstract]   [Full Text] [Related]  

  • 77. Effect of lansoprazole on Helicobacter pylori.
    Lamouliatte H
    Clin Ther; 1993; 15 Suppl B():32-6. PubMed ID: 8205593
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 79. Effect of bismuth and nitecapone on acetaldehyde production by Helicobacter pylori.
    Salmela KS; Roine RP; Höök-Nikanne J; Kosunen TU; Salaspuro M
    Scand J Gastroenterol; 1994 Jun; 29(6):528-31. PubMed ID: 8079111
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
    Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.